pentobarbital will decrease the level or influence of roflumilast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not encouraged; sturdy cytochrome P450 enzyme inducers minimize systemic publicity to roflumilast and should decrease the therapeutic performanceDosages of barbiturates has to be individualize